Adherence-enhancing interventions for active antiretroviral therapy in sub-Saharan Africa: A systematic review and meta-analysis

Sexual Health

Volumn 11, Issue 3, 2014, Pages 230-239

  Mathes, Tim ^a   Antoine, Sunya Lee ^a   Pieper, Dawid ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

AIDS; directly observed therapy; HIV; SMS; text messaging.

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; COMPARATIVE STUDY; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MORTALITY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84905239096     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH14025     Document Type: Review

References (36)

1. United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. Global Report. Geneva: UNAIDS; 2012.
2. Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, Urquhart J. Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 2005; 24(17): 2719-31. doi:10.1002/sim.2130
3. + cell count is 0.200 to 0.350 x 109 cells/L. Ann Intern Med 2003; 139(10): 810-6. doi: 10.7326/0003-4819-139-10-200311180-00008
4. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191(3): 339-47. doi:10.1086/427192
5. Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010; 24(3): 395-403. doi:10.1097/QAD.0b013e328335cd8a
6. Reda AA, Biadgilign S. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Res Treat 2012; 574656. doi:10.1155/2012/574656
7. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296(6): 679-90. doi:10.1001/jama.296.6.679
8. World Health Organisation (WHO). Adherence to long-term therapies-evidence for action. Geneva: WHO; 2003.
9. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11(12): 942-51. doi:10.1016/S1473-3099 (11)70181-5
10. Schwartländer B, Grubb I, Perriëns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368(9534): 541-6. doi:10.1016/S0140-6736(06)69164-2
11. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11(1): 44-7. doi:10.1111/j.1524-4733.2007.00213.x
12. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011; 45(3): 372-9. doi:10.1345/aph.1P587
13. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) Rilpivirin-Nutzenbewertung gemäß § 35a SGB V Dossierbewertung. Cologne: IQWIG; 2012.
14. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
15. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8(3): e1000422. doi:10.1371/journal. pmed.1000422
16. Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010; 24(9): 1273-80.
17. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007; 46(2): 238-44. doi:10.1097/QAI. 0b013e318153f7ba
18. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376(9755): 1838-45. doi:10.1016/S0140-6736(10) 61997-6
19. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Short-and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 2008; 48(5): 611-9. doi:10.1097/QAI. 0b013e3181806bf1
20. Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills EJ, Smieja M, et al. The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PLoS ONE 2012; 7(12): e46909. doi:10.1371/journal.pone.0046909
21. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 2010; 54(2): 167-79.
22. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12(5): 687-94. doi:10.1111/j.1365-3156.2007.01830.x
23. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3(11): e438. doi:10.1371/journal.pmed.0030438
24. Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, Ramsay CR, et al. Contamination in trials of educational interventions. Health Technol Assess 2007; 11(43): iii, ix-107.
25. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010; 340: c2073. doi:10.1136/bmj.c2073
26. Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Trop Med Int Health 2010; 15: 16-33. doi:10.1111/j.1365-3156.2010. 02510.x
27. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 2010; 5(1): 70-7. doi:10.1097/COH.0b013e328333ad61
28. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45(1): 4-8. doi:10.1097/QAI.0b013e318050d8c2
29. Buscher A, Hartman C, Kallen MA, Giordano TP. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive, HIV patients. HIV Clin Trials 2011; 12 (5): 244-54. doi:10.1310/hct1205-244
30. Gorenoi V, Schoenermark MP, Hagen A. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes (structured abstract). Cologne: German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information; 2007.
31. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2: CD000011.
32. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011; 25(6): 825-34. doi:10.1097/QAD.0b013e32834380c1
33. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev 2012; 3: CD009756.
34. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010; 3: CD004371.
35. Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al. Development and validation of the HIV Medication Readiness Scale. Assessment 2007; 14(4): 408-16. doi:10.1177/1073191107304295
36. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 2013; 73(6): 545-62. doi:10.1007/s40265-013-0041-3